Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

BIZARRE: Rigl - What They Never Told You

This ‘Darling’ Pharma Stock Is Hitting New Highs

Rigel Pharmaceuticals (RIGL) is showing exceptional momentum, setting new 52-week highs on Aug. 22. Shares are up nearly 243% over the past year. The stock is trading above key moving averages and is supported by several “Strong Buy” analyst ratings. Fundamentals show impressive projected earnings growth this year, but both...

3 Pharma Stocks With May Potential

3 Pharma Stocks With May Potential

The pharma sector is poised for strong growth thanks to rising demand for personalized treatments, an aging population, advancements in pharma technology, and innovative approaches to drug discovery and manufacturing. Hence, investors could consider buying quality pharmaceutical stocks such as Zoetis (ZTS), Rigel Pharmaceuticals (RIGL), and Kamada (KMDA) with May…

1 Pharma Stock to Buy for Under $1 This December

1 Pharma Stock to Buy for Under $1 This December

Pharma company Rigel’s (RIGL) REZLIDHIA recently achieved the U.S. Food and Drug Administration’s approval for treating relapsed or refractory acute myeloid leukemia, helping the stock to soar. RIGL shares have gained more than 30% over the past month. Given the industry tailwinds, RIGL might be the ideal stock to buy…

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Why Rigel Pharmaceuticals Shares Are Falling Today

Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) shares are trading lower after the company announced data from the FORWARD Phase 3 clinical trial of Fostamatinib did not demonstrate statistical significance in the primary efficacy endpoint.

Rigel Pharmaceuticals' Fostamatinib Flunks In Late-Stage Rare Blood Disorder Trial

Rigel Pharmaceuticals Inc (NASDAQ: RIGL) shares are falling on disappointing data from the FORWARD Phase 3 trial of fostamatinib in patients with warm autoimmune hemolytic anemia (wAIHA).

Recap: Rigel Pharmaceuticals Q1 Earnings

Rigel Pharmaceuticals (NASDAQ:RIGL) reported its Q1 earnings results on Tuesday, May 3, 2022 at 04:01 PM. Here's what investors need to know about the announcement.

Preview: Rigel Pharmaceuticals's Earnings

Rigel Pharmaceuticals (NASDAQ:RIGL) is set to give its latest quarterly earnings report on Tuesday, 2022-05-03. Here's what investors need to know before the announcement. Analysts estimate that Rigel Pharmaceuticals will report an earnings per share (EPS) of $-0.14.

inkl

Read news from The Economist, FT, and more,
with one subscription

Looking Into Rigel Pharmaceuticals's Return On Capital Employed

Looking Into Rigel Pharmaceuticals's Return On Capital Employed

Rigel Pharmaceuticals (NASDAQ:RIGL) brought in sales totaling $20.41 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 8.06%, resulting in a loss of $22.64 million.

Recap: Rigel Pharmaceuticals Q4 Earnings

Recap: Rigel Pharmaceuticals Q4 Earnings

Rigel Pharmaceuticals (NASDAQ:RIGL) reported its Q4 earnings results on Tuesday, March 1, 2022 at 04:01 PM. Here's what investors need to know about the announcement.

1

People

Jim Van Meerten

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Medical Pharmaceuticals

Medical – Pharmaceuticals

Rigel Pharmaceuticals

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play